DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report issued to clients and investors on Wednesday. The brokerage set a “hold” rating on the stock.

A number of other brokerages have also commented on DBVT. HC Wainwright upped their price objective on shares of DBV Technologies from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Thursday, October 24th. JMP Securities reissued a “market outperform” rating and issued a $5.00 price target on shares of DBV Technologies in a research report on Tuesday, September 24th.

DBV Technologies Stock Performance

Shares of DBVT opened at $0.74 on Wednesday. The company has a 50-day simple moving average of $0.75 and a 200-day simple moving average of $0.92. The firm has a market capitalization of $71.07 million, a P/E ratio of -0.78 and a beta of 0.66. DBV Technologies has a 52 week low of $0.50 and a 52 week high of $2.14.

Institutional Inflows and Outflows

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. boosted its stake in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,568,909 shares of the company’s stock after acquiring an additional 327,345 shares during the quarter. DBV Technologies accounts for 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th largest position. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.